Neurolutions, Inc., a MedTech company with offices in Santa Cruz, California, and St. Louis, Missouri, announced that the U.S. FDA granted De Novo market authorization for its groundbreaking IpsiHand Upper Extremity Rehabilitation System.
“The approval of the IpsiHand System represents an important step forward in the care and rehabilitation of stroke patients,” said Leo Petrossian, Ph.D., CEO of Neurolutions. “For the first time, we are able to combine advanced robotics with brain-computer interface technology to augment traditional stroke rehabilitation, allowing patients to improve upper extremity function after stroke.”
There are approximately 6 million stroke survivors living in the United States. Approximately 800,000 American adults experience a stroke each year, of which approximately 300,000 are left with upper extremity movement dysfunction. Muscular weakness or partial paralysis frequently persists into the chronic stage of stroke with 65% of chronic stroke patients reporting reduced motor function six months after stroke.
The IpsiHand system takes advantage of the uninjured side of the brain to trigger the opening and closing of a robotic exoskeleton placed over the affected arm. The system also includes a tablet computer and an EEG-based biometric headset. The system translates brain signals from the uninjured, or ipsilateral, a hemisphere of the brain, into a movement of the exoskeleton. As a result, when the patient thinks about opening their hand, the device physically opens the patient’s impaired hand. This ability to physically open and close the patient’s hand based on the patient’s thoughts facilitates muscle reeducation, improving upper extremity rehabilitation. Developed by a team of innovators in Silicon Valley and neuroscientists from Washington University in St. Louis. the neuro-prosthetic and robotic capabilities of the IpsiHand System have been shown in clinical trials to provide both statistically and clinically significant outcomes for chronic stroke patients, reports GlobeNewsWire.
“The IpsiHand System represents the cutting-edge of medical technology and is the first FDA-authorized brain-computer interface for robotic rehabilitation,” said Kern Bhugra, Chief Operating Officer of Neurolutions. “This milestone would never have been possible without the partnership with the FDA, who diligently worked with us to ensure we brought this benefit to patients.”
“Progress in improving rehabilitation outcomes for stroke patients has historically been challenging, but the market authorization of the IpsiHand System promises to usher in a bright future for our stroke patients and allows us to support their recovery throughout the rehabilitation process,” said Eric Leuthardt, MD, Chief Scientific Officer of Neurolutions and Chief of Division of Neurotechnology and Professor of Neurosurgery and Neuroscience at Washington University.
IpsiHand is indicated for use in patients 18 and older undergoing stroke rehabilitation to facilitate muscle re-education and for maintaining or increasing range of motion. All participants in an unblinded 40-patient study over 12 weeks demonstrated motor function improvement with the device over the trial. Adverse events reported included minor fatigue and discomfort and temporary skin redness.
Neurolutions intends to begin commercialization of the IpsiHand Upper Extremity Rehabilitation System in the U.S. later this year.